BMO Capital Downgrades United Therapeutics Corp. (UTHR) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JPMorgan Downgrades United Therapeutics Corp. (UTHR) to Underweight
October 24, 2012 6:49 AM EDTJPMorgan downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Neutral to Underweight with a price target of $40.00 (from $50.00) following CRL from FDA for Oral Treprostinil.
For an analyst ratings summary and ratings history on United Therapeutics Corp.... More
United Therapeutics (UTHR) Receives CRL from FDA for Oral Treprostinil
October 23, 2012 4:16 PM EDTUnited Therapeutics Corporation (NASDAQ: UTHR) announced today that it received a complete response letter from the United States Food and Drug Administration (FDA) declining to approve its new drug application (NDA) for treprostinil diethanolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial... More
